AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01471652 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nutraceutical supplements
Description: 1. CoEnzyme Q10: oral gel capsule bid~2. Acetyl L-carnitine: oral capsule bid~3. Alpha Lipoic Acid: oral tablet qd~4. Docosahexaenoic acid: oral gel capsule bid
Study NCT01471652 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Capsule form to imitate the following nutraceuticals:~1. Placebo 1: oral gel capsule bid~2. Placebo 2: oral capsule bid~3. Placebo 3: oral tablet qd~4. Placebo 4: oral gel capsule bid
Study NCT02378870 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Osteodex
Description: Osteodex 3.0 mg/kg given every two week, maximum 13 times.
Study NCT02378870 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03087227 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NEUTROSIS
Description: evaluate a shared health information system (NEUTROSIS) for home-hospital management of febrile neutropenia after anti-tumor chemotherapy
Study NCT02740751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Still-Tee
Description: The mothers of the babies will receive Still-Tee galactogogue tea
Study NCT02740751 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Still-Tee
Description: The mothers of the babies will receive Still-Tee galactogogue tea
Study NCT00766727 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: GLYDe Dressing
Description: Wound dressing intended to minimize scar formation
Study NCT01001091 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AL-38583 ophthalmic solution
Study NCT01001091 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: AL-38583 ophthalmic solution vehicle
Description: Inactive ingredients used as a placebo comparator
Study NCT01001091 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dexamethasone ophthalmic suspension, 0.1%
Study NCT02612766 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Pure, uncontaminated oats
Study NCT01750034 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Closed method
Description: Subjects will have their wounds managed by covering with gauze and changing this gauze 3 to 7 times per week.
Study NCT01750034 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Open method
Description: Subjects will have their burns managed by keeping the wounds exposed to the air.
Study NCT03148834 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Controlled Reperfusion
Description: Patients will be treated in the occluded coronary with a solution of venous blood and Dextran, prior to the Stenting procedure.~Controlled Reperfusion PCI consists of crossing the culprit lesion with guidewire and then advancing a balloon (over the wire) to the distal segment of the culprit vessel. Proximal to the main distal branch, inflate the balloon to low atmospheres, remove the guide wire and inject the solution through the light of the balloon. Then reposition the guidewire, perform angioplasty as usual on the lesion. If there is a large residual thrombus load and at the operator's discretion, change the balloon by a manual thromboaspiration catheter and use it.~Then perform stenting of the lesion. The solution will be given with a 1 cc syringe as a slow bolus, controlling symptoms and ST segment response.~The compounds in solution are venous blood drawn from the patient after administration of heparin and mixed with dextran in a 3/1 ratio.
Study NCT00071006 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AG-013736 (Axitinib)
Description: patients were treated with axitinib at starting dose of 5 mg BID continuous dosing.
Study NCT02705534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sofosbuvir
Description: 400 mg, included in a combination pill with 90 mg ledipasvir
Study NCT02705534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ledipasvir
Description: 90 mg, included in a combination pill with 400 mg sofosbuvir
Study NCT02705534 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin
Description: 1000 mg/day if \<75 kg, 1200 mg/day for >75 kg. Divided into two daily doses
Study NCT01092312 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Vanguard Knee System with Signature Knee Guide
Description: Use of Signature Knee Guide
Study NCT01092312 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Vanguard Knee System with conventional Instruments
Description: Vanguard Knee System with conventional Instruments
Study NCT02264925 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Deep Brain Stimulation with Medtronic Activa PC+S systems
Description: Deep Brain Stimulation of VIM.
Study NCT02331459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Multicomponent training intervention
Description: Intervention characteristics: 24weeks, 5days/week, 60min/session Day 1, 3 and 5 15 min (a) 40 min (b) 5 min (d) Day 2 and 4 15 min (a) 40 min (c) 5 min (d)~Legend:~min. =minutes a = Proprioception exercises, postural sway and dynamic balance, coordination and flexibility of the lumbo-pelvic area b = Aerobic training 65% maximal Heart rate c = Strength training arms and legs d = Stretching
Study NCT02331459 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Nutritional intervention
Description: Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)
Study NCT00581958 — intervention group
Intervention type: OTHER
Intervention: Blood Samples
Description: blood (approximately two 4 ml; equivalent to less than 2 tablespoon) and urine (a cup of urine) samples or testing a total of three times. Blood will be drawn and urine will be collected once before radiation treatment and twice after first radiation treatment.
Study NCT00360334 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day
Study NCT00360334 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: insulin glargine
Description: subcutaneous injection, titrated to target blood glucose level, once a day
Study NCT02211469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BMS-986104
Study NCT02331459 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nutritional intervention
Description: Enrolled patients will receive nutritional information on optimal daily energy intake, ensuring at least a daily protein intake of 1 g. of by kg of weight.~Calcium plus vitamin D (total amount 1200 mg calcium plus 800 IU of vitamin D) Vitamin D will be provided if calcidiol (Cldl) blood levels are lower than 30 ng/ml.~Cldl 20-29 ng/dl it will provide calciferol 20.000 IU every 15 days (3 months) Cldl 10-19 ng/dl it will provide calciferol 20.000 IU every 10 days (3 months) Cldl 1-9 ng/dl it will provide calciferol 20.000 IU every 7 days (3 months)
Study NCT02100215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
Study NCT02100215 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
Study NCT02100215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Common readings and educational handouts
Description: Participants in all groups have common readings related to policies for nursing care in acute care facilities. There will be additional handouts related to performing safety checks and a focused physical assessment.
Study NCT02100215 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Expert Modeling
Description: 70 minutes of expert modeling videos
Study NCT02100215 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Voice Over Power Point
Description: 60 minutes of Voice Over PowerPoint presentations
Study NCT03147209 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Health Coaching
Description: This intervention will consist of health coaching, goal setting and self directed activities to improve strength and balance.
Study NCT02474420 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferasirox
Description: Deferasirox administered per standard of care by the treating physician
Study NCT00860171 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Autologous Hematopoietic Stem Cell Transplantation
Description: Autologous stem cells given via central catheter
Study NCT00910000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vorinostat
Study NCT00910000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Study NCT00910000 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Study NCT00860171 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Iodine I 131 Monoclonal Antibody BC8
Description: Given IV
Study NCT00860171 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT03009422 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Local application pentostam
Study NCT03009422 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intra-lisional pentostam
Study NCT03009422 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: fractional CO2 laser
Study NCT03261609 — intervention group
Intervention type: OTHER
Intervention: preterm birth
Description: The study compares young adult subjects born premature (\< 29 weeks) versus term (-> 37 weeks)
Study NCT02741141 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: New partograph based on the studies of Neal and Lowe
Description: The partograph designed by Neal and Lowe includes an action line which if crossed permits an active management of labour.~Eventually, the only difference between the two arms is the moment when the active management of labour is started.~The oxytocin is administrated according to the department protocol.
Study NCT02211469 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT04131439 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Computed Tomography and Magnetic resonance imaging
Description: Preoperative imaging for patients undergoing cochlear implants
Study NCT04002297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: zanubrutinib
Description: Administered as two 80 mg capsules by mouth twice a day
Study NCT04002297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bendamustine
Description: Administered intravenously at a dose of 90 mg/m2/day on Days 1 and 2 of Cycles 1 to 6
Study NCT04002297 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rituximab
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Study NCT02741141 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Classical partograph
Description: Classical partograph used as standard care
Study NCT00961363 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sitagliptin
Description: sitagliptin 100 mg per day
Study NCT00961363 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT04206371 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Defibrillator threshold testing
Description: Under general or local anesthesia. Induction of Ventricular Fibrillation or R-wave synchronized shock
Study NCT01994265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Warfarin
Description: Warfarin once daily, at fast, targeting INR between 2 and 3
Study NCT01994265 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Dabigatran
Study NCT04002297 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rituximab
Description: Administered intravenously at a dose of 375 mg/m2 on Day 1 of Cycles 1 to 6
Study NCT01598909 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Arnica
Description: Application of Arnica ointment periorbitally
Study NCT01598909 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo ointment
Description: Application of Arnica ointment, twice a day, for the period of one week.
Study NCT02472301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: cowpeas complementary food
Description: cowpeas supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
Study NCT02472301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: corn-soy flour
Description: Corn-soy flour supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
Study NCT02472301 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: common bean complementary food
Description: common bean supplementary food that will be approximately 15% of the calculated total daily intake. Children will receive the food for 12 months.
Study NCT03354273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET MPI
Description: Flurpiridaz (18F) Injection. All participants received 2 IV boluses of Flurpiridaz (18F) Injection in a large peripheral vein: 1 at rest and 1 during stress. The dosages of Flurpiridaz (18F) Injection administered at rest and during stress conditions did not exceed a total of 14 mCi (520 MBq) for an individual participant.
Study NCT03354273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SPECT MPI
Description: SPECT imaging was used 99mTc-based myocardial tracers. SPECT agents utilised for the purposes of this clinical study was administered as per American Society of Nuclear Cardiology or European Association of Cardiovascular Imaging standards, where applicable. All participants undergone SPECT MPI.
Study NCT03354273 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pharmacological stress agents
Description: Pharmacologic stress agents were restricted to the following 3 agents, as permitted by local marketing authorisations and availability: adenosine, dipyridamole, and regadenoson. Administration was through an IV line.
Study NCT03445416 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: POL arm
Description: A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
Study NCT03445416 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Comparison arm
Description: A popular opinion leader intervention designed to increase routine vaccination among young black men who have sex with men.
Study NCT00508742 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: 13-valent Pneumococcal Conjugate Vaccine
Description: 1 dose at 2, 4, 6 and 12 months of age
Study NCT00508742 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: 7 valent pneumococcal conjugate vaccine
Description: 1 dose at 2, 4, 6 and 12 months of age
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cisplatin
Description: cisplatin at 30 mg/m2 on days 1 and 15
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: capecitabine
Description: capecitabine at 1250 mg/ m2 days 1-28
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: gemcitabine
Description: gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: gemcitabine
Description: gemcitabine at 800 mg/ m2 on days 1 and 15 in arm A; at 1000 mg/m2 on days 1, 8 and 15 in arm B
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: nab-paclitaxel
Description: nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
Study NCT01730222 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: nab-paclitaxel
Description: nab-paclitaxel at the recommended phase II dose day 1 and 15 in arm A; at 125 mg/m2 on days 1, 8 and 15 in arm B
Study NCT03428139 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency
Description: Each patient in this group was treated with PRFT on the affected DRG at 42°C for 120 seconds.
Study NCT03428139 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: pulsed radiofrequency plus alpha lipoic acid
Description: Each patient in this group was treated with PRFT as in group I plus oral alpha lipoic acid (ALA) 600 mg (Thiotacid 600 mg, EVA PHARMA, Egypt) three times per day (1800mg/day) for 3 weeks then 600mg once daily for 2 weeks.
Study NCT01424657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: ERCP
Description: Endoscopic retrograde cholangiopancreatography
Study NCT01424657 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: MRCP
Description: magnetic resonance cholangiopancreatography
Study NCT00483119 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous immunoglobulin
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Study NCT00483119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: intravenous immunoglobulin
Description: Gamunex 10% 500/mg/kg/day x four days per cycle total of four cycles
Study NCT00483119 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cyclophosphamide
Description: cyclophosphamide dose of 2mg/kg/day divided into three-times daily oral administration
Study NCT04409509 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody
Description: Garadacimab, Factor XIIa Antagonist Monoclonal Antibody administered intravenously
Study NCT04409509 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: CSL312 diluent administered intravenously
Study NCT01345227 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Intra bone marrow islet infusion
Description: A needle for bone marrow aspiration (14 G) will be inserted into the superior-posterior iliac crest and islet suspension (1:2.5; tissue:Ringer's Lactate solution) will be infused. The entire intraBM-injection procedure last 8-15 min from the beginning of anaesthesia (short propofol sedation).
Study NCT01225601 — intervention group
Intervention type: BEHAVIORAL
Intervention: Tabacco discontinuation
Description: Tabacco discontinuation
Study NCT04299126 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: high absorption pad for blood and pus
Description: High absorption pad for blood and pus will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
Study NCT04299126 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: commercial wound dressing
Description: Commercial wound dressing will be covered on half of split-thickness skin graft donor site wound until the wound has healed.
Study NCT02454621 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Volitional help sheet
Description: Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
Study NCT02454621 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Volitional help sheet
Description: Participants are asked to form implementation intentions using a volitional help sheet (Armitage, 2008).
Study NCT02822027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: human gamma globulin
Description: human gamma globulin for preterm infants with encephalopathy of prematurities
Study NCT02822027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: human gamma globulin
Description: human gamma globulin for preterm infants with encephalopathy of prematurities
Study NCT02822027 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: non-human gamma globulin
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities
Study NCT02822027 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: non-human gamma globulin
Description: Non-human gamma globulin for preterm infants with encephalopathy of prematurities
Study NCT02233673 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Financial incentives
Description: Participants receive a behavioral intervention and financial incentives for meeting gestational weight gain goals.
Study NCT03066466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atorvastatin
Description: Oral medication given to prevent graft versus host disease in bone marrow transplant.
Study NCT03066466 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: IV medication given to prevent graft versus host disease in bone marrow transplant.